The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 25, 2022

Filed:

Aug. 17, 2016
Applicant:

Seoul National University R&db Foundation, Seoul, KR;

Inventors:

Kyungho Choi, Goyang-si, KR;

Hyung-Bae Park, Seoul, KR;

Ji Eun Lee, Goyang-si, KR;

Yumi Oh, Goyang-si, KR;

Ki-Hyun Kim, Seoul, KR;

Soohyun Kim, Seoul, KR;

Hyori Kim, Seoul, KR;

Junho Chung, Seongnam-si, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 47/68 (2017.01); C12N 15/85 (2006.01); A61K 39/395 (2006.01); A61K 38/17 (2006.01); C07K 16/16 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6819 (2017.08); A61K 35/17 (2013.01); A61K 38/17 (2013.01); A61K 39/395 (2013.01); A61K 39/39558 (2013.01); C07K 16/16 (2013.01); C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); C12N 15/85 (2013.01); A61P 35/00 (2018.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/10 (2013.01);
Abstract

The present invention relates to chimeric antibody receptors with anti-cotinine antibodies linked, and use thereof. A T cell presenting the chimeric antibody receptor on the surface secretes interferon gamma specifically for a target molecule of a cotinine-conjugated binding molecule that is added together therewith and induces cell death of the cell expressing the target molecule by the T cell. On the contrary, by administering a cytotoxic agent conjugated with cotinine, cell death of the chimeric antigen receptor T cell is induced. Therefore, if necessary, a cytotoxic agent conjugated with cotinine can be administered to remove the chimeric antigen receptor T cells that have been already administered, thereby suppressing immune side effects due to hyperactivity of T cells. Thus, the chimeric antigen receptor to which the anti-cotinine antibody is linked can be effectively and safely used for the treatment of cancer.


Find Patent Forward Citations

Loading…